Preclinical News and Research

RSS

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

MicroStockProfit.com announces an investment report featuring Rexahn Pharmaceuticals Inc. The report includes financial, comparative and investment analyses, and industry information you need to know to make an educated investment decision.

3 Jun 2010

Data on Nanosphere Verisens PSA assay to be presented at AUA annual meeting

At the annual meeting of the American Urological Association, data using the Nanosphere Verisens™ ultra-sensitive PSA assay (research use only) will be highlighted as one of less than 40 abstracts that were singled out by the Association for a special session for journalists.

3 Jun 2010

UTHealth, UH awarded $150,000 grant to find cure and better treatments for Alzheimer's disease

Cure Alzheimer's Fund recently awarded the University of Texas Health Science Center at Houston and the University of Houston a $150,000 grant to fund innovative research on Alzheimer's disease, which currently affects 5.3 million Americans and their families and is the most common cause of dementia in the elderly.

3 Jun 2010

Entelos' T1D PhysioLab platform published in Clinical and Experimental Immunology

Entelos, Inc. has announced a publication in the peer-reviewed journal Clinical and Experimental Immunology describing the Type 1 Diabetes (T1D) PhysioLab® platform, an in silico solution for rapidly streamlining preclinical research through the evaluation of alternative scenarios for therapeutic strategies.

2 Jun 2010

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

Q Therapeutics, Inc. announced today that Piotr Walczak, M.D., of Johns Hopkins University has received notification of a $1,000,000 grant to be awarded by the Maryland Stem Cell Research Fund (MSCRF) which will enable further study of Q's human neural glial cell product Q-Cells® in preclinical models of demyelinating disease.

2 Jun 2010

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

EntreMed, Inc., today announced the publication of preclinical results for its clinical-stage Aurora A/angiogenic kinase inhibitor, ENMD-2076, in human colorectal cancer xenograft models. The results of the study, conducted by EntreMed collaborators at the University of Colorado School of Medicine, were published in the June 1, 2010 issue of Clinical Cancer Research (Vol. 16, Issue 11).

2 Jun 2010

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

Asuragen, Inc., a leader in molecular diagnostics and RNA-based pharmacogenomics services, announced today that it has obtained a non-exclusive license to incorporate the BRAF V600E mutation sequence into Asuragen's molecular diagnostic products. The license was obtained from Johns Hopkins University and includes the use of the BRAF V600E mutation as a component of diagnostic test kits and for use in Asuragen's CLIA laboratory for clinical research and patient testing.

2 Jun 2010

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Raptor Pharmaceutical Corp., announced that the Company has acquired an exclusive worldwide license to intellectual property related to the potential treatment of Huntington's Disease from the Weizmann Institute of Science in Israel and Niigata University in Japan. In addition, Raptor has added Professor Lawrence Steinman, M.D., an inventor on the Weizmann patent, to its Advisory Board.

2 Jun 2010

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Onyx Pharmaceuticals, Inc. today announced the initiation of a Phase 1 study of ONX 0912, an oral proteasome inhibitor, in patients with advanced refractory or recurrent solid tumors.

2 Jun 2010

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Oncolytics Biotech Inc. today announced that it has received approval from the Belgian Federal Agency for Medicines and Health Products (FAMHP) to conduct its Phase 3 trial examining REOLYSIN in combination with paclitaxel and carboplatin in patients with platinum-refractory head and neck cancers. This is the same trial that was agreed to by U.S. Food and Drug Administration (FDA) under the Special Protocol Assessment (SPA) process and the U.K. Medicines and Healthcare products Regulatory Agency (MHRA).

1 Jun 2010

Europe spends just 5% of total cancer research funds on metastases

On average, about five percent of total cancer research funding is spent on investigating metastases (the spread of cancer cells around the body) in Europe, yet metastatic disease is the direct or indirect cause of 90 percent of all cancer deaths, according to an editorial in the European Journal of Cancer (EJC).

1 Jun 2010

U.S. Department of Defense OTT initiative to replace scars and defects with healthy, functional tissues

A two-year, $12 million contract with the U.S. Department of Defense Office of Technology Transition (OTT) will jumpstart human trials of three innovative research programs that aim to replace scars and defects with healthy, functional tissues, announced officials of the University of Pittsburgh and the McGowan Institute for Regenerative Medicine today at the Institute's Second Annual Open Session, Soldiers and Sailors Memorial Hall, Oakland.

31 May 2010

NewYork-Presbyterian Hospital/Columbia University Medical Center announce presentations at American Urological Association meeting

Physician-scientists from NewYork-Presbyterian Hospital/Columbia University Medical Center will present their latest research findings at the American Urological Association Annual Meeting in San Francisco, May 29 to June 3.

31 May 2010

Focused Ultrasound Surgery Foundation welcomes abstracts on MR-guided focused ultrasound

The Focused Ultrasound Surgery Foundation has announced that abstract submissions and registration are now open for the 2nd International Symposium on MR-guided Focused Ultrasound and can be accessed online at www.fusfoundation.org/symposium.

29 May 2010

HUYA Bioscience International forms strategic partnership with School of Chinese Materia Medica of BUCM

HUYA Bioscience International, a leader in globalizing China's biopharmaceutical innovation, today announced a strategic partnership with the School of Chinese Materia Medica of the Beijing University of Chinese Medicine (BUCM). As one of a series of collaborations that HUYA has established with China's leading research and development institutions, the agreement demonstrates HUYA's visionary commitment to enabling and accelerating the global development and commercialization of novel biopharmaceutical products originating in China.

29 May 2010

Preimplantation Factor essential for pregnancy to succeed: Study

Researchers at Yale School of Medicine and their colleagues at the Society for the Investigation of Early Pregnancy have helped clarify the function of a unique protein called Preimplantation Factor, which is produced by healthy embryos to direct embryo attachment and help the mother adapt to pregnancy.

29 May 2010

Bioheart to establish two Centers of Excellence to provide cell therapy procedures for patients with CHF, PAD

Bioheart, Inc., announced today plans for establishing two Centers of Excellence in the Middle East to provide its cell therapy procedures to patients suffering from congestive heart failure and peripheral arterial disease. Dr. Karl E. Groth, Chairman and CEO, and Peggy A. Farley, Chief Operating and Financial Officer, are now in that region holding discussions and performing site inspections.

29 May 2010

Neptune's revenues increased by 8% for fiscal year ended February 28, 2010

Neptune Technologies & Bioressources Inc. today reports its consolidated financial results for the fiscal year ended February 28, 2010, announces the implementation of a shareholder rights plan and provides fiscal year highlights.

28 May 2010

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

CytRx Corporation, a biopharmaceutical company specializing in oncology, today announced that its drug candidate bafetinib (formerly known as INNO-406) demonstrated statistically significant inhibition of glioblastoma multiforme cell lines in a preclinical trial. Glioblastoma multiforme is the most common and aggressive primary adult brain tumor.

28 May 2010

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Progenics Pharmaceuticals, Inc. today announced the presentation of preclinical data on novel monoclonal antibodies against toxins produced by the bacterium Clostridium difficile (C. difficile). The monoclonal antibodies effectively neutralized the cell-killing activities of the toxins in vitro and significantly improved survival in a stringent animal model of C. difficile infection. C. difficile is the leading cause of hospital-acquired diarrhea in the United States and represents a growing global public health challenge.

28 May 2010

Preclinical News and Research

MicroStockProfit.com releases investment report featuring Rexahn Pharmaceuticals

Data on Nanosphere Verisens PSA assay to be presented at AUA annual meeting

UTHealth, UH awarded $150,000 grant to find cure and better treatments for Alzheimer's disease

Entelos' T1D PhysioLab platform published in Clinical and Experimental Immunology

Johns Hopkins professor receives $1M MSCRF grant to study glial cells for treating myelin disorders

ENMD-2076 demonstrates antitumor activity against murine xenograft models of CRC: Study

Asuragen obtains license to integrate BRAF V600E mutation sequence into its molecular diagnostic products

Raptor Pharmaceutical acquires exclusive license to intellectual property for Huntington's Disease treatment

Onyx Pharmaceuticals commences Phase 1 study of ONX 0912 oral proteasome inhibitor for cancer

Belgian FAMHP approves Oncolytics' Phase 3 combination trial of REOLYSIN in head and neck cancers

Europe spends just 5% of total cancer research funds on metastases

U.S. Department of Defense OTT initiative to replace scars and defects with healthy, functional tissues

NewYork-Presbyterian Hospital/Columbia University Medical Center announce presentations at American Urological Association meeting

Focused Ultrasound Surgery Foundation welcomes abstracts on MR-guided focused ultrasound

HUYA Bioscience International forms strategic partnership with School of Chinese Materia Medica of BUCM

Preimplantation Factor essential for pregnancy to succeed: Study

Bioheart to establish two Centers of Excellence to provide cell therapy procedures for patients with CHF, PAD

Neptune's revenues increased by 8% for fiscal year ended February 28, 2010

CytRx's bafetinib demonstrates significant inhibition of glioblastoma multiforme cell lines in preclinical trial

Progenics presents preclinical data on novel monoclonal antibodies against toxins produced by C. difficile

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest Life Science News